Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Puffin Rock Characters Plush Toy Set
anil1961
Updated:
Nov 7, 2026
Toyota Vitz scp10 For Sale
Lakmal Bandara
Updated:
Nov 4, 2026
Kandy
Welcome all my all new pet shop Bark.lk
dilumrane
Updated:
Nov 2, 2026
Windows RDP Only Rs.500 a month
Blogerwiki
Updated:
Nov 1, 2026
Ad icon
V2ray VPN for Tunneling
hu KANNA
Updated:
Oct 22, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
Novavax NVX-CoV2373 reports high efficacy
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 26989433" data-attributes="member: 562115"><p>Novavax NVX-CoV2373 is a <strong>prefusion protein </strong>vaccine candidate. It uses Novavax' proprietary recombinant nanoparticle technology with their saponin-based Matrix-M adjuvant technology. Matrix-M is composed of 40 nanometer particles based on saponin extracted from the Quillaja saponaria Molina bark together with cholesterol and phospholipid.</p><p></p><p>The vaccine is based on an engineered baculovirus containing a gene for a modified SARS-CoV-2 virus spike protein. The baculovirus then infects a culture of Sf9 moth cells, which generate the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle each displaying up to 14 spike proteins.</p><p></p><p>Studies with a total of 25,452 volunteers from the US and Mexico. About 48.2% of participants were female, 75.9% were White, 11% were Black/African American, 6.2% were Native American/Alaska Native, and 21.5% identified as Hispanic/Latino. The median age was 47, and about 11.8% of participants were 65 years or older. About 17,312 were administered two doses of the NVX-CoV2373 vaccine, while 8,140 received a placebo.</p><p></p><p>The results were - It was 93.6% protective against Alpha. 100% effective against SARS-CoV-2 strains that were <strong>neither</strong> variants of concerns <strong>nor</strong> variants of interest. Vaccine effectiveness was <strong>92.6% against any variant of concern or variant of interest</strong>.</p><p></p><p>Mild to moderate side effects were observed with vaccinated individuals. The adverse events increased after the second dose. No severe safety concerns were reported after vaccination.</p><p></p><p>Those who show hesitancy for mRNA vaccines can opt for this vaccine.</p></blockquote><p></p>
[QUOTE="imhotep, post: 26989433, member: 562115"] Novavax NVX-CoV2373 is a [B]prefusion protein [/B]vaccine candidate. It uses Novavax' proprietary recombinant nanoparticle technology with their saponin-based Matrix-M adjuvant technology. Matrix-M is composed of 40 nanometer particles based on saponin extracted from the Quillaja saponaria Molina bark together with cholesterol and phospholipid. The vaccine is based on an engineered baculovirus containing a gene for a modified SARS-CoV-2 virus spike protein. The baculovirus then infects a culture of Sf9 moth cells, which generate the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle each displaying up to 14 spike proteins. Studies with a total of 25,452 volunteers from the US and Mexico. About 48.2% of participants were female, 75.9% were White, 11% were Black/African American, 6.2% were Native American/Alaska Native, and 21.5% identified as Hispanic/Latino. The median age was 47, and about 11.8% of participants were 65 years or older. About 17,312 were administered two doses of the NVX-CoV2373 vaccine, while 8,140 received a placebo. The results were - It was 93.6% protective against Alpha. 100% effective against SARS-CoV-2 strains that were [B]neither[/B] variants of concerns [B]nor[/B] variants of interest. Vaccine effectiveness was [B]92.6% against any variant of concern or variant of interest[/B]. Mild to moderate side effects were observed with vaccinated individuals. The adverse events increased after the second dose. No severe safety concerns were reported after vaccination. Those who show hesitancy for mRNA vaccines can opt for this vaccine. [/QUOTE]
Insert quotes…
Verification
Hath warak paha keeyada? (hatha wadikireema paha)
Post reply
Top
Bottom